Daiichi Sankyo and Ranbaxy Laboratories have announced plans to introduce innovator products of the former in Mexico through the marketing division that was created last year within latter's Mexican subsidiary, Ranbaxy Mexico.
The companies have agreed to commercialize olmesartan medoxomil, an antihypertensive discovered by Daiichi Sankyo, in Mexico.
The companies have also agreed to promote prasugrel, an antiplatelet co-developed by Daiichi Sankyo and Eli Lilly, in Mexico. Prasugrel will be co-promoted by Lilly's affiliate in Mexico.
Share this: 
Del.icio.us |
Email This | 
Printer Friendly
